The U.S. Food and Drug Administration is set to rule on five closely watched treatments in August from Moderna, Lantheus Holdings, Bristol Myers Squibb, Capricor Therapeutics and Ultragenyx Pharmaceutical.Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to…
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We…
Global investment firm CapVest Partners LLP is doubling down on nuclear medicine after portfolio company Curium agreed to acquire Lantheus Holdings Inc. (NASDAQ:LNTH) in a deal valued at up to $8 billion.Kate Briant, Chair of Curium’s Board of Directors and a Senior Partner at CapVest, said the acq…
Lantheus agreed to be acquired by Curium for $102.50 per share in cash plus up to $12.00 per share in contingent value rights.Key Highlights:Original SEC Filing: Lantheus Holdings, Inc. [ LNTH ] - 8-K - Aug. 03, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying impo…
Explore more price target data and ratings for Lantheus Holdings, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Lantheus Holdings, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. Thi…
Shares of Lantheus Holdings Inc. (LNTH) fell 3% in after-hours trading on Monday following a report that Curium, the CapVest Partners-backed nuclear medicine company, is in advanced talks to acquire the radiopharmaceutical firm in a $7 billion deal, below the company’s market capitalization.Bloombe…
